Moberg Pharma completes enrolment for Phase 3 nail fungus study in North America.

NORDIC BUSINESS REPORT-October 6, 2023-Moberg Pharma completes enrolment for Phase 3 nail fungus study in North America

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Swedish pharmaceutical company Moberg Pharma AB (STO:MOB) announced on Friday that it has recruited 384 patients with onychomycosis (nail fungus) for its ongoing Phase 3 study of MOB-015 in North America.

MOB-015 is a topical formulation of terbinafine, developed to enable effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use.

The aim of the trial is to provide a key part of the clinical data set for registration and commercialisation of MOB-015 in the Unnited States. Topline results are expected in January 2025.

Patients will be evaluated over 52 weeks, with the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT